Flow cytometry

JA Joyce Aarts
AC Arjan van Caam
XC Xinlai Chen
RM Renoud J. Marijnissen
MH Monique M. Helsen
BW Birgitte Walgreen
EV Elly L. Vitters
FL Fons A. van de Loo
PL Peter L. van Lent
PK Peter M. van der Kraan
MK Marije I. Koenders
request Request a Protocol
ask Ask a question
Favorite

Cells were stimulated for 4 h with phorbol myristate acetate (PMA; 50 ng/ml; Sigma-Aldrich), ionomycin (1 µg/ml; Sigma-Aldrich), and the Golgi-traffic inhibitor Brefeldin (1 µl/ml: BD Biosciences, Franklin Lakes, NJ, USA). Next, cells were stained with anti-CD3-FITC (145-2C11) (BioLegend), anti-CD4-PerCP/Cy5.5 (RM4-4) (BioLegend), fixable viability dye eFluor 780 (eBioscience), fixed and permeabilized using Cytofix/Cytoperm (BD Biosciences), followed by intra-cellular staining with anti-IL-17-PE (TC11-18H10.1) (BioLegend), anti-FOXP3-Alexa Fluor 647 (150D) (BioLegend) and anti-RORγt-BV421 (Q31-378) (BD Biosciences). The gating of T cells was as follows. First, cells were gated in an FSC-A vs. SSC-A dot plot, and subsequently gated in FSC-W vs. FSC-A and SSC-W vs. SSC-A dot plots to eliminate doublets. Living cells were gated based on FVD, and next CD3 + /CD4 + cells were gated on the basis of FMO controls. Finally, IL-17 + and FOXP3 + cells were determined in this gate as markers for Th17 and Treg cells, respectively. Cells were analyzed on the Cytoflex and subsequently using Kaluza software version 2.1.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A